Nanobiotix - ADR
NBTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.45B
Close$
$-5.57
118.7% downside
Current Fair Value
118.7% downsideOvervalued by 118.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.45 Billion |
|---|---|
| Enterprise Value | $1.48 Billion |
| Earnings per Share | $-0.5 |
| Beta | 0.57 |
| Outstanding Shares | 48,883,075 |
Return
| Return on Equity | 314.58% |
|---|---|
| Return on Assets | -81.83% |
| Return on Invested Capital | -165.35% |
Valuation & Multiples
| P/E Ratio | -25.56 |
|---|---|
| PEG | -4.69 |
| Price to Sales | - |
| Price to Book Ratio | -29.7 |
| Enterprise Value to Revenue | 119.3 |
| Enterprise Value to EBIT | -21.17 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -4.28 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
$23.56 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 27, 2027
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$26.64 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.50%▼ 0.61% |
|---|---|
| Total Invested | $175.24M▼ 19.75% |
| Investors Holding | 2▼ 17.00% |
About Nanobiotix
89 employees
CEO: Laurent Levy
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of cry...